COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response

https://doi.org/10.1158/2643-3230.bcd-20-0177

2.

Dhodapkar

MV

,

Dhodapkar

KM

,

Ahmed

R

.

Viral immunity and vaccines in hematologic malignancies: implications for COVID-19

.

Blood Cancer Discov

.

2021 Jan

;

2

(

1

):

9

–

12

.

.

3.

Passamonti

F

,

Cattaneo

C

,

Arcaini

L

,

Bruna

R

,

Cavo

M

,

Merli

F

,

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

.

Lancet Haematol

.

2020 Oct

;

7

(

10

):

e737

–

45

.

4.

Mossuto

S

,

Attardi

E

,

Alesiani

F

,

Angelucci

E

,

Balleari

E

,

Bernardi

M

,

SARS-CoV-2 in myelodysplastic syndromes: a snapshot from early Italian experience

.

HemaSphere

.

2020 Oct

;

4

(

5

):

e483

.

5.

Lamure

S

,

Duléry

R

,

Di Blasi

R

,

Chauchet

A

,

Laureana

C

,

Deau-Fischer

B

,

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study

.

EClin Med

.

2020 Oct 13

;

27

:

100549

.

6.

Pagano

L

,

Salmanton-García

J

,

Marchesi

F

,

Busca

A

,

Corradini

P

,

Hoenigl

M

,

COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA)

.

J Hematol Oncol

.

2021 Oct 14

;

14

(

1

):

168

.

7.

Kim

JS

,

Lee

KH

,

Kim

GE

,

Kim

S

,

Yang

JW

,

Li

H

,

Clinical characteristics and mortality of patients with hematologic malignancies and COVID-19: a systematic review

.

Eur Rev Med Pharmacol Sci

.

2020 Nov

;

24

(

22

):

11926

–

33

.

8.

Maia

C

,

Martín-Sánchez

E

,

Garcés

JJ

,

De Cerio

ALD

,

Inogés

S

,

Landecho

MF

,

Immunologic characterization of COVID-19 patients with hematological cancer

.

Haematologica

.

2020 Dec 17

;

106

(

5

):

1457

–

60

.

9.

Mathew

D

,

Giles

JR

,

Baxter

AE

,

Oldridge

DA

,

Greenplate

AR

,

Wu

JE

,

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

.

Science

.

2020 Sep 4

;

369

(

6508

):

eabc8511

.

https://doi.org/10.1007/s00705-021-05091-1

10.

Shabbir

S

,

Raza

MH

,

Arshad

M

,

Khan

MJ

.

The interplay between the immune system and SARS-CoV-2 in COVID-19 patients

.

Arch Virol

.

2021 Aug

;

166

(

8

):

2109

–

17

.

.

11.

Kuri-Cervantes

L

,

Pampena

MB

,

Meng

W

,

Rosenfeld

AM

,

Ittner

CAG

,

Weisman

AR

,

Comprehensive mapping of immune perturbations associated with severe COVID-19

.

Sci Immunol

.

2020 Jul 15

;

5

(

49

):

eabd7114

.

12.

Tahaghoghi-Hajghorbani

S

,

Zafari

P

,

Masoumi

E

,

Rajabinejad

M

,

Jafari-Shakib

R

,

Hasani

B

,

The role of dysregulated immune responses in COVID-19 pathogenesis

.

Virus Res

.

2020 Dec

;

290

:

198197

.

13.

Roel

E

,

Pistillo

A

,

Recalde

M

,

Fernández-Bertolín

S

,

Aragón

M

,

Soerjomataram

I

,

Cancer and the risk of COVID-19 diagnosis, hospitalisation, and death: a population-based multi-state cohort study including 4,618,377 adults in Catalonia, Spain

.

Int J Cancer

.

2021 Oct 16

.

14.

Levy

I

,

Lavi

A

,

Zimran

E

,

Grisariu

S

,

Aumann

S

,

Itchaki

G

,

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

.

Leuk Lymphoma

.

2021 Dec

;

62

(

14

):

3384

–

93

.

15.

Basquiera

AL

,

García

MJ

,

Martinez Rolón

J

,

Olmedo

J

,

Laviano

J

,

Burgos

R

,

Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine society of hematology

.

Medicina

.

2021

;

81

(

4

):

536

–

45

.

16.

Gupta

A

,

Desai

N

,

Sanjeev

,

Chauhan

P

,

Nityanand

S

,

Hashim

Z

,

Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India

.

Ann Hematol

.

2021 Sep 24

.

17.

Russell

B

,

Moss

CL

,

Shah

V

,

Ko

TK

,

Palmer

K

,

Sylva

R

,

Risk of COVID-19 death in cancer patients: an analysis from Guy’s cancer centre and King’s college hospital in London

.

Br J Cancer

.

2021 Sep

;

125

(

7

):

939

–

47

.

18.

Suárez-García

I

,

Perales-Fraile

I

,

González-García

A

,

Muñoz-Blanco

A

,

Manzano

L

,

Fabregate

M

,

In-hospital mortality among immunosuppressed patients with COVID-19: analysis from a national cohort in Spain

.

PLoS One

.

2021 Aug 3

;

16

(

8

):

e0255524

.

19.

Visco

C

,

Marcheselli

L

,

Mina

R

,

Sassone

M

,

Guidetti

A

,

Penna

D

,

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

.

Blood Adv

.

2021 Oct 13

.

20.

Arcani

R

,

Colle

J

,

Cauchois

R

,

Koubi

M

,

Jarrot

PA

,

Jean

R

,

Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue

.

Ann Hematol

.

2021 Nov

;

100

(

11

):

2799

–

803

.

21.

Knudtzen

FC

,

Jensen

TG

,

Lindvig

SO

,

Rasmussen

LD

,

Madsen

LW

,

Hoegh

SV

,

SARS-CoV-2 viral load as a predictor for disease severity in outpatients and hospitalised patients with COVID-19: a prospective cohort study

.

PLoS One

.

2021 Oct 12

;

16

(

10

):

e0258421

.

22.

Barbui

T

,

De Stefano

V

,

Alvarez-Larran

A

,

Iurlo

A

,

Masciulli

A

,

Carobbio

A

,

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

.

Blood Cancer J

.

2021 Feb 4

;

11

(

2

):

21

.

23.

García-Suárez

J

,

de la Cruz

J

,

Cedillo

Á

,

Llamas

P

,

Duarte

R

,

Jiménez-Yuste

V

,

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

.

J Hematol Oncol

.

2020 Oct 8

;

13

(

1

):

133

.

24.

Palanques-Pastor

T

,

Megías-Vericat

JE

,

Martínez

P

,

López Lorenzo

JL

,

Cornago Navascués

J

,

Rodriguez Macias

G

,

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

.

Leuk Lymphoma

.

2021 Dec

;

62

(

12

):

2928

–

38

.

25.

Stahl

M

,

Narendra

V

,

Jee

J

,

Derkach

A

,

Maloy

M

,

Geyer

MB

,

Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality

.

Leuk Lymphoma

.

2021 Aug

;

62

(

8

):

1940

–

8

.

26.

Fagundes

EM

,

Neto

NN

,

Caldas

LM

,

Aragão

JR

,

Gloria

ABF

,

Leite

LG

,

Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil

.

Ann Hematol

.

2021 Sep 17

.

27.

Ribera

JM

,

Morgades

M

,

Coll

R

,

Barba

P

,

López-Lorenzo

J-L

,

Montesinos

P

,

Frequency, clinical characteristics and outcome of adults with acute lymphoblastic leukemia and COVID 19 infection in the first vs. second pandemic wave in Spain

.

Clin Lymphoma Myeloma Leuk

.

2021 Oct

;

21

(

10

):

e801

–

9

.

28.

Scarfò

L

,

Chatzikonstantinou

T

,

Rigolin

GM

,

Quaresmini

G

,

Motta

M

,

Vitale

C

,

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

.

Leukemia

.

2020 Sep

;

34

(

9

):

2354

–

63

.

29.

Chatzikonstantinou

T

,

Kapetanakis

A

,

Scarfò

L

,

Karakatsoulis

G

,

Allsup

D

,

Cabrero

AA

,

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

.

Leukemia

.

2021 Dec

;

35

(

12

):

3444

–

54

.

30.

Roeker

LE

,

Eyre

TA

,

Thompson

MC

,

Lamanna

N

,

Coltoff

AR

,

Davids

MS

,

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

.

Blood

.

2021 Nov 4

;

138

(

18

):

1768

–

73

.

31.

Blixt

L

,

Bogdanovic

G

,

Buggert

M

,

Gao

Y

,

Hober

S

,

Healy

K

,

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients

.

Leukemia

.

2021 Sep 25

.

32.

Malard

F

,

Genthon

A

,

Brissot

E

,

van de Wyngaert

Z

,

Marjanovic

Z

,

Ikhlef

S

,

COVID-19 outcomes in patients with hematologic disease

.

Bone Marrow Transplant

.

2020 Nov

;

55

(

11

):

2180

–

4

.

33.

Duléry

R

,

Lamure

S

,

Delord

M

,

Di Blasi

R

,

Chauchet

A

,

Hueso

T

,

Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy

.

Am J Hematol

.

2021 Aug 1

;

96

(

8

):

934

–

44

.

34.

Gaitzsch

E

,

Passerini

V

,

Khatamzas

E

,

Strobl

CD

,

Muenchhoff

M

,

Scherer

C

,

COVID-19 in patients receiving CD20-depleting Immunochemotherapy for B-cell lymphoma

.

HemaSphere

.

2021 Jul

;

5

(

7

):

e603

.

35.

Calderón-Parra

J

,

Múñez-Rubio

E

,

Fernández-Cruz

A

,

García Sánchez

MC

,

Maderuelo-González

E

,

López-Dosil

M

,

Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies

.

Clin Infect Dis

.

2021 Aug 12

.

36.

Booth

S

,

Curley

HM

,

Varnai

C

,

Arnold

R

,

Lee

LYW

,

Campton

NA

,

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy

.

Br J Haematol

.

2021 Nov 10

.

37.

Barbui

T

,

Vannucchi

AM

,

Alvarez-Larran

A

,

Iurlo

A

,

Masciulli

A

,

Carobbio

A

,

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

.

Leukemia

.

2021 Feb

;

35

(

2

):

485

–

93

.

38.

Piñana

JL

,

Martino

R

,

García-García

I

,

Parody

R

,

Morales

MD

,

Benzo

G

,

Risk factors and outcome of COVID-19 in patients with hematological malignancies

.

Exp Hematol Oncol

.

2020 Aug 25

;

9

:

21

.

39.

Mushtaq

MU

,

Shahzad

M

,

Chaudhary

SG

,

Luder

M

,

Ahmed

N

,

Abdelhakim

H

,

Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients

.

Transplant Cel Ther

.

2021 Sep

;

27

(

9

):

796e1

.

https://doi.org/10.1017/ice.2020.1273

40.

Unable to find information for 11985810.

41.

Fontana

LM

,

Villamagna

AH

,

Sikka

MK

,

McGregor

JC

.

Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature

.

Infect Control Hosp Epidemiol

.

2021 Jun

;

42

(

6

):

659

–

68

.

.

42.

Fox-Lewis

A

,

Fox-Lewis

S

,

Beaumont

J

,

Drinković

D

,

Harrower

J

,

Howe

K

,

SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study

.

Pathology

.

2021 Jun

;

53

(

4

):

530

–

5

.

43.

Bullard

J

,

Dust

K

,

Funk

D

,

Strong

JE

,

Alexander

D

,

Garnett

L

,

Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples

.

Clin Infect Dis

.

2020 Dec 17

;

71

(

10

):

2663

–

6

.

44.

Babady

NE

,

Cohen

B

,

McClure

T

,

Chow

K

,

Caldararo

M

,

Jani

K

,

Variable duration of viral shedding in cancer patients with COVID-19

.

Infect Control Hosp Epidemiol

.

2021 Aug 27

:

1

–

15

.

45.

Kawasuji

H

,

Morinaga

Y

,

Tani

H

,

Yoshida

Y

,

Takegoshi

Y

,

Kaneda

M

,

SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19

.

J Med Virol

.

2021 Aug 19

.

https://doi.org/10.1016/j.jinf.2021.01.022

46.

Belsky

JA

,

Tullius

BP

,

Lamb

MG

,

Sayegh

R

,

Stanek

JR

,

Auletta

JJ

.

COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients

.

J Infect

.

2021 Mar

;

82

(

3

):

329

–

38

.

.

47.

Xu

K

,

Chen

Y

,

Yuan

J

,

Yi

P

,

Ding

C

,

Wu

W

,

Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19)

.

Clin Infect Dis

.

2020 Jul 28

;

71

(

15

):

799

–

806

.

48.

Choi

B

,

Choudhary

MC

,

Regan

J

,

Sparks

JA

,

Padera

RF

,

Qiu

X

,

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

.

N Engl J Med

.

2020 Dec 3

;

383

(

23

):

2291

–

3

.

49.

Karataş

A

,

İnkaya

AÇ

,

Demiroğlu

H

,

Aksu

S

,

Haziyev

T

,

Çınar

OE

,

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

.

Transfus Apher Sci

.

2020 Oct

;

59

(

5

):

102871

.

50.

Mowrer

CT

,

Creager

H

,

Cawcutt

K

,

Birge

J

,

Lyden

E

,

Van Schooneveld

TC

,

Evaluation of cycle threshold values at deisolation

.

Infect Control Hosp Epidemiol

.

2021 Apr 6

:

1

–

3

.

https://doi.org/10.1016/j.cell.2021.02.029

51.

Schultze

JL

,

Aschenbrenner

AC

.

COVID-19 and the human innate immune system

.

Cell

.

2021 Apr 1

;

184

(

7

):

1671

–

92

.

.

52.

Abdul-Jawad

S

,

Baù

L

,

Alaguthurai

T

,

Del Molino Del Barrio

I

,

Laing

AG

,

Hayday

TS

,

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

.

Cancer Cell

.

2021 Feb 8

;

39

(

2

):

257

.

53.

Bilich

T

,

Roerden

M

,

Maringer

Y

,

Nelde

A

,

Heitmann

JS

,

Dubbelaar

ML

,

Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer

.

Cancer Discov

.

2021 Aug

;

11

(

8

):

1982

–

95

.

https://doi.org/10.1371/journal.pone.0240751

54.

Fu

YQ

,

Sun

YL

,

Lu

SW

,

Yang

Y

,

Wang

Y

,

Xu

F

.

Effect of blood analysis and immune function on the prognosis of patients with COVID-19

.

PLoS One

.

2020 Oct 30

;

15

(

10

):

e0240751

.

.

https://doi.org/10.1186/s12985-021-01597-x

55.

Yin

SW

,

Zhou

Z

,

Wang

JL

,

Deng

YF

,

Jing

H

,

Qiu

Y

.

Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study

.

Virol J

.

2021 Jun 12

;

18

(

1

):

126

.

.

https://doi.org/10.1016/j.jneuroim.2021.577632

56.

Danladi

J

,

Sabir

H

.

Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis

.

J Neuroimmunol

.

2021 Sep 15

;

358

:

577632

.

.

https://doi.org/10.1016/j.intimp.2021.108255

57.

Attiq

A

,

Yao

LJ

,

Afzal

S

,

Khan

MA

.

The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19

.

Int Immunopharmacol

.

2021 Oct 15

;

101

(

Pt B

):

108255

.

.

58.

Yokota

S

,

Miyamae

T

,

Kuroiwa

Y

,

Nishioka

K

.

Novel coronavirus disease 2019 (COVID-19) and cytokine storms for more effective treatments from an inflammatory pathophysiology

.

J Clin Med

.

2021 Feb 17

;

10

(

4

):

801

.

59.

Vijenthira

A

,

Gong

IY

,

Fox

TA

,

Booth

S

,

Cook

G

,

Fattizzo

B

,

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3,377 patients

.

Blood

.

2020 Dec 17

;

136

(

25

):

2881

–

92

.

60.

Fendler

A

,

Au

L

,

Shepherd

S

,

Byrne

F

,

Cerrone

M

,

Boos

L

,

Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

.

Res Sq

.

2021 Sep 20

.

61.

Bange

EM

,

Han

NA

,

Wileyto

P

,

Kim

JY

,

Gouma

S

,

Robinson

J

,

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

.

Nat Med

.

2021 Jul

;

27

(

7

):

1280

–

9

.

62.

Qin

C

,

Zhou

L

,

Hu

Z

,

Zhang

S

,

Yang

S

,

Tao

Y

,

Dysregulation of Immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

.

Clin Infect Dis

.

2020 Jul 28

;

71

(

15

):

762

–

8

.

63.

Kyriakoulis

KG

,

Kollias

A

,

Poulakou

G

,

Kyriakoulis

IG

,

Trontzas

IP

,

Charpidou

A

,

The effect of anakinra in hospitalized patients with COVID-19: an updated systematic review and meta-analysis

.

J Clin Med

.

2021 Sep 28

;

10

(

19

):

4462

.

https://doi.org/10.1016/S2213-2600(20)30556-7

64.

CORIMUNO-19 Collaborative Group

.

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

.

Lancet Respir Med

.

2021 Mar

;

9

(

3

):

295

–

304

.

.

65.

Kyriazopoulou

E

,

Huet

T

,

Cavalli

G

,

Gori

A

,

Kyprianou

M

,

Pickkers

P

,

Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

.

Lancet Rheumatol

.

2021 Oct

;

3

(

10

):

e690

–

7

.

66.

Ngamprasertchai

T

,

Kajeekul

R

,

Sivakorn

C

,

Ruenroegnboon

N

,

Luvira

V

,

Siripoon

T

,

Efficacy and safety of immunomodulators in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

.

Infect Dis Ther

.

2021 Nov 10

.

67.

Caricchio

R

,

Abbate

A

,

Gordeev

I

,

Meng

J

,

Hsue

PY

,

Neogi

T

,

Effect of canakinumab versus placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial

.

JAMA

.

2021 Jul 20

;

326

(

3

):

230

–

9

.

68.

de la Calle

C

,

López-Medrano

F

,

Pablos

JL

,

Lora-Tamayo

J

,

Maestro-de la Calle

G

,

Sánchez-Fernández

M

,

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

.

Int J Infect Dis

.

2021 Apr

;

105

:

319

–

25

.

69.

Villegas

C

,

Poza

M

,

Talayero

P

,

Teller

JMC

,

Zafra

D

,

Garcia

C

,

IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection

.

Ann Hematol

.

2020 Dec

;

99

(

12

):

2953

–

6

.

70.

Kalil

AC

,

Patterson

TF

,

Mehta

AK

,

Tomashek

KM

,

Wolfe

CR

,

Ghazaryan

V

,

Baricitinib plus remdesivir for hospitalized adults with Covid-19

.

N Engl J Med

.

2021 Mar 4

;

384

(

9

):

795

–

807

.

71.

Marconi

VC

,

Ramanan

AV

,

de Bono

S

,

Kartman

CE

,

Krishnan

V

,

Liao

R

,

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

.

Lancet Respir Med

.

2021 Dec

;

9

(

12

):

1407

–

18

.

https://doi.org/10.1038/s41375-021-01266-6

72.

Chen

CX

,

Wang

JJ

,

Li

H

,

Yuan

LT

,

Gale

RP

,

Liang

Y

.

JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis

.

Leukemia

.

2021 Sep

;

35

(

9

):

2616

–

20

.

.

https://doi.org/10.1159/000510179

73.

Rojas

P

,

Sarmiento

M

.

JAK/STAT pathway inhibition may be a promising therapy for COVID-19-related hyperinflammation in hematologic patients

.

Acta Haematol

.

2021

;

144

(

3

):

314

–

8

.

.

https://doi.org/10.1182/bloodadvances.2020003768

74.

Jacobs

CF

,

Eldering

E

,

Kater

AP

.

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

.

Blood Adv

.

2021 Feb 9

;

5

(

3

):

913

–

25

.

.

75.

CAS-ViewAlert [Internet] [cited 2021 Nov 18]. Available from: https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103144.

76.

COVID-19 treatment guidelines [Internet]. [cited 2021 Nov 18]. Available from: https://www.covid19treatmentguidelines.nih.gov/.

77.

Giesen

N

,

Sprute

R

,

Rüthrich

M

,

Khodamoradi

Y

,

Mellinghoff

SC

,

Beutel

G

,

2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy

.

Eur J Cancer

.

2021 Apr

;

147

:

154

–

60

.

78.

Shoumariyeh

K

,

Biavasco

F

,

Ihorst

G

,

Rieg

S

,

Nieters

A

,

Kern

WV

,

Covid-19 in patients with hematological and solid cancers at a comprehensive cancer center in Germany

.

Cancer Med

.

2020 Nov

;

9

(

22

):

8412

–

22

.

https://doi.org/10.1080/10428194.2021.1924370

79.

Banerjee

R

,

Fakhri

B

,

Shah

N

.

Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome

.

Leuk Lymphoma

.

2021 Nov

;

62

(

11

):

2600

–

11

.

.

https://doi.org/10.1093/rheumatology/keq343

80.

Campbell

L

,

Chen

C

,

Bhagat

SS

,

Parker

RA

,

Östör

AJ

.

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

.

Rheumatology

.

2011 Mar

;

50

(

3

):

552

–

62

.

.

81.

Stone

JH

,

Frigault

MJ

,

Serling-Boyd

NJ

,

Fernandes

AD

,

Harvey

L

,

Foulkes

AS

,

Efficacy of tocilizumab in patients hospitalized with Covid-19

.

N Engl J Med

.

2020 Dec 10

;

383

(

24

):

2333

–

44

.

82.

Rosas

IO

,

Diaz

G

,

Gottlieb

RL

,

Lobo

SM

,

Robinson

P

,

Hunter

BD

,

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

.

Intensive Care Med

.

2021 Nov

;

47

(

11

):

1258

–

70

.

83.

Veiga

VC

,

Prats

JAGG

,

Farias

DLC

,

Rosa

RG

,

Dourado

LK

,

Zampieri

FG

,

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

.

BMJ

.

2021 Jan 20

;

372

:

n84

.

84.

Salama

C

,

Han

J

,

Yau

L

,

Reiss

WG

,

Kramer

B

,

Neidhart

JD

,

Tocilizumab in patients hospitalized with Covid-19 pneumonia

.

N Engl J Med

.

2021 Jan 7

;

384

(

1

):

20

–

30

.

85.

Hermine

O

,

Mariette

X

,

Tharaux

PL

,

Resche-Rigon

M

,

Porcher

R

,

Ravaud

P

,

Effect of Tocilizumab versus usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

.

JAMA Intern Med

.

2021 Jan 1

;

181

(

1

):

32

–

40

.

86.

Investigators REMAP-CAP

;

Gordon

AC

,

Mouncey

PR

,

Al-Beidh

F

,

Rowan

KM

,

Nichol

AD

,

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

.

N Engl J Med

.

2021 Apr 22

;

384

(

16

):

1491

–

502

.

87.

Moreno-González

G

,

Mussetti

A

,

Albasanz-Puig

A

,

Salvador

I

,

Sureda

A

,

Gudiol

C

,

A phase I/II clinical trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial

.

Trials

.

2021 Feb 5

;

22

(

1

):

116

.

88.

Sparks

JA

,

Wallace

ZS

,

Seet

AM

,

Gianfrancesco

MA

,

Izadi

Z

,

Hyrich

KL

,

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry

.

Ann Rheum Dis

.

2021 Sep

;

80

(

9

):

1137

–

46

.

89.

Regierer

AC

,

Hasseli

R

,

Schäfer

M

,

Hoyer

BF

,

Krause

A

,

Lorenz

HM

,

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

.

RMD Open

.

2021 Oct

;

7

(

3

):

e001896

.

90.

Raiker

R

,

DeYoung

C

,

Pakhchanian

H

,

Ahmed

S

,

Kavadichanda

C

,

Gupta

L

,

Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States

.

Semin Arthritis Rheum

.

2021 Oct

;

51

(

5

):

1057

–

66

.

91.

Fakharian

A

,

Barati

S

,

Mirenayat

M

,

Rezaei

M

,

Haseli

S

,

Torkaman

P

,

Evaluation of adalimumab effects in managing severe cases of COVID-19: a randomized controlled trial

.

Int Immunopharmacol

.

2021 Oct

;

99

:

107961

.

92.

Fu

W

,

Chen

C

,

Chen

XL

,

Wang

K

,

Zuo

P

,

Liu

Y

,

A U-shaped association between baseline neutrophil count and COVID-19-related mortality: a retrospective cohort study

.

J Med Virol

.

2021 Jul

;

93

(

7

):

4265

–

72

.

93.

Grivas

P

,

Khaki

AR

,

Wise-Draper

TM

,

French

B

,

Hennessy

C

,

Hsu

CY

,

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer consortium

.

Ann Oncol

.

2021 Jun

;

32

(

6

):

787

–

800

.

https://doi.org/10.1007/s00277-020-04103-5

94.

Liu

X

,

Zhang

R

,

He

G

.

Hematological findings in coronavirus disease 2019: indications of progression of disease

.

Ann Hematol

.

2020 Jul

;

99

(

7

):

1421

–

8

.

.

95.

Henry

B

,

Cheruiyot

I

,

Vikse

J

,

Mutua

V

,

Kipkorir

V

,

Benoit

J

,

Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis

.

Acta Biomed

.

2020 Sep 7

;

91

(

3

):

e2020008

.

96.

Liu

J

,

Liu

Y

,

Xiang

P

,

Pu

L

,

Xiong

H

,

Li

C

,

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

.

J Transl Med

.

2020 May 20

;

18

(

1

):

206

.

97.

Barnes

BJ

,

Adrover

JM

,

Baxter-Stoltzfus

A

,

Borczuk

A

,

Cools-Lartigue

J

,

Crawford

JM

,

Targeting potential drivers of COVID-19: neutrophil extracellular traps

.

J Exp Med

.

2020 Jun 1

;

217

(

6

):

e20200652

.

98.

Effah

CY

,

Drokow

EK

,

Agboyibor

C

,

Ding

L

,

He

S

,

Liu

S

,

Neutrophil-dependent immunity during pulmonary infections and inflammations

.

Front Immunol

.

2021 Oct 19

;

12

:

689866

.

99.

Cheng

LL

,

Guan

WJ

,

Duan

CY

,

Zhang

NF

,

Lei

CL

,

Hu

Y

,

Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial

.

JAMA Intern Med

.

2021 Jan 1

;

181

(

1

):

71

–

8

.

https://doi.org/10.1080/23744235.2020.1790031

100.

Chen

GB

,

Lin

JT

,

Zhang

Z

,

Liu

L

.

Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19

.

Infect Dis

.

2020 Oct

;

52

(

10

):

759

–

61

.

.

101.

Griffiths

EA

,

Alwan

LM

,

Bachiashvili

K

,

Brown

A

,

Cool

R

,

Curtin

P

,

Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic

.

J Natl Compr Canc Netw

.

2020 Sep 1

:

1

–

4

.

https://doi.org/10.2217/imt-2021-0219

102.

Lasagna

A

,

Muzzana

M

,

Pedrazzoli

P

.

Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research

.

Immunotherapy

.

2021 Dec

;

13

(

17

):

1369

–

72

.

.

103.

Sereno

M

,

Jimenez-Gordo

AM

,

Baena-Espinar

J

,

Aguado

C

,

Mielgo

X

,

Pertejo

A

,

A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with granulocyte-colony stimulating factor (G-CSF): a comparative analysis

.

Cancers

.

2021 Aug 20

;

13

(

16

):

4205

.

104.

Nawar

T

,

Morjaria

S

,

Kaltsas

A

,

Patel

D

,

Perez-Johnston

R

,

Daniyan

AF

,

Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow?

Am J Hematol

.

2020 Aug

;

95

(

8

):

E210

–

3

.

105.

Zhang

AW

,

Morjaria

S

,

Kaltsas

A

,

Hohl

TM

,

Parameswaran

R

,

Patel

D

,

The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection

.

Clin Infect Dis

.

2021 Jun 10

.

106.

Bao

C

,

Tao

X

,

Cui

W

,

Hao

Y

,

Zheng

S

,

Yi

B

,

Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients

.

Exp Hematol Oncol

.

2021 Jan 27

;

10

(

1

):

5

.

107.

Li

M

,

Guo

W

,

Dong

Y

,

Wang

X

,

Dai

D

,

Liu

X

,

Elevated exhaustion levels of NK and CD8+ T cells as indicators for progression and prognosis of COVID-19 disease

.

Front Immunol

.

2020 Oct 14

;

11

:

580237

.

108.

Kalicińska

E

,

Szymczak

D

,

Zińczuk

A

,

Adamik

B

,

Smiechowicz

J

,

Skalec

T

,

Immunosuppression as a hallmark of critical COVID-19: prospective study

.

Cells

.

2021 May 23

;

10

(

6

):

1293

.

109.

Kalicińska

E

,

Szymczak

D

,

Andrasiak

I

,

Bogucka-Fedorczuk

A

,

Zińczuk

A

,

Szymański

W

,

Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study

.

Transl Oncol

.

2021 Jan

;

14

(

1

):

100943

.

110.

Liu

W

,

Li

Z

,

He

W

,

Yu

D

,

Wang

P

,

Cai

L

,

Impact of chemotherapy on lymphocytes and serological memory in recovered COVID-19 patients with acute leukemia

.

J Cancer

.

2021 Mar 1

;

12

(

8

):

2450

–

5

.

111.

Cattaneo

C

,

Cancelli

V

,

Imberti

L

,

Dobbs

K

,

Sottini

A

,

Pagani

C

,

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

.

Blood Cancer J

.

2021 Sep 14

;

11

(

9

):

151

.

112.

Huang

W

,

Berube

J

,

McNamara

M

,

Saksena

S

,

Hartman

M

,

Arshad

T

,

Lymphocyte subset counts in COVID-19 patients: a meta-analysis

.

Cytometry A

.

2020 Aug

;

97

(

8

):

772

–

6

.

113.

Wang

F

,

Nie

J

,

Wang

H

,

Zhao

Q

,

Xiong

Y

,

Deng

L

,

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

.

J Infect Dis

.

2020 May 11

;

221

(

11

):

1762

–

9

.

114.

Sosa-Hernández

VA

,

Torres-Ruíz

J

,

Cervantes-Díaz

R

,

Romero-Ramírez

S

,

Páez-Franco

JC

,

Meza-Sánchez

DE

,

B cell subsets as severity-associated signatures in COVID-19 patients

.

Front Immunol

.

2020 Dec 3

;

11

:

611004

.

115.

Lenti

MV

,

Aronico

N

,

Pellegrino

I

,

Boveri

E

,

Giuffrida

P

,

Borrelli de Andreis

F

,

Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19

.

Sci Rep

.

2020 Nov 30

;

10

(

1

):

20836

.

116.

Shah

V

,

Ko Ko

T

,

Zuckerman

M

,

Vidler

J

,

Sharif

S

,

Mehra

V

,

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s college hospital experience

.

Br J Haematol

.

2020 Sep

;

190

(

5

):

e279

–

82

.

https://doi.org/10.1136/jitc-2021-002630

117.

Goldman

JD

,

Robinson

PC

,

Uldrick

TS

,

Ljungman

P

.

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

.

J Immunother Cancer

.

2021 Jun

;

9

(

6

):

e002630

.

.

118.

Cattaneo

C

,

Daffini

R

,

Pagani

C

,

Salvetti

M

,

Mancini

V

,

Borlenghi

E

,

Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19

.

Cancer

.

2020 Dec 1

;

126

(

23

):

5069

–

76

.

119.

Brown

LAK

,

Moran

E

,

Goodman

A

,

Baxendale

H

,

Bermingham

W

,

Buckland

M

,

Treatment of chronic or relapsing COVID-19 in immunodeficiency

.

J Allergy Clin Immunol

.

2021 Nov 12

.

120.

Patel

NJ

,

D’Silva

KM

,

Hsu

TYT

,

DiIorio

M

,

Fu

X

,

Cook

C

,

COVID-19 outcomes among users of CD20 inhibitors for immune-mediated diseases: a comparative cohort study

.

Med Rxiv

.

2021 Aug 9

.

121.

Boekel

L

,

Steenhuis

M

,

Hooijberg

F

,

Besten

YR

,

van Kempen

ZLE

,

Kummer

LY

,

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

.

Lancet Rheumatol

.

2021 Nov

;

3

(

11

):

e778

–

88

.

https://doi.org/10.1182/bloodadvances.2021004629

122.

Vijenthira

A

,

Gong

I

,

Betschel

SD

,

Cheung

M

,

Hicks

LK

.

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

.

Blood Adv

.

2021 Jun 21

;

5

(

12

):

2624

–

43

.

.

123.

Mato

AR

,

Roeker

LE

,

Lamanna

N

,

Allan

JN

,

Leslie

L

,

Pagel

JM

,

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

.

Blood

.

2020 Sep 3

;

136

(

10

):

1134

–

43

.

124.

Wilkinson

T

,

Dixon

R

,

Page

C

,

Carroll

M

,

Griffiths

G

,

Ho

LP

,

ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial

.

Trials

.

2020 Jul 31

;

21

(

1

):

691

.

125.

Treon

SP

,

Castillo

JJ

,

Skarbnik

AP

,

Soumerai

JD

,

Ghobrial

IM

,

Guerrera

ML

,

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

.

Blood

.

2020 May 21

;

135

(

21

):

1912

–

5

.

126.

Lujan

JV

,

Lengerke-Diaz

PA

,

Jacobs

C

,

Moreno-Cortes

EF

,

Ramirez-Segura

CA

,

Choi

MY

,

Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

.

Haematologica

.

2020 Jan

;

105

(

1

):

e22

–

5

.

127.

Fiorcari

S

,

Maffei

R

,

Audrito

V

,

Martinelli

S

,

Ten Hacken

E

,

Zucchini

P

,

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia

.

Oncotarget

.

2016 Oct 4

;

7

(

40

):

65968

–

81

.

https://doi.org/10.1126/sciimmunol.abe8063

128.

Karlsson

AC

,

Humbert

M

,

Buggert

M

.

The known unknowns of T cell immunity to COVID-19

.

Sci Immunol

.

2020 Nov 18

;

5

(

53

):

eabe8063

.

.

129.

Jiang

M

,

Guo

Y

,

Luo

Q

,

Huang

Z

,

Zhao

R

,

Liu

S

,

T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019

.

J Infect Dis

.

2020 Jun 29

;

222

(

2

):

198

–

202

.

130.

Lagadinou

M

,

Zareifopoulos

N

,

Gkentzi

D

,

Sampsonas

F

,

Kostopoulou

E

,

Marangos

M

,

Alterations in lymphocyte subsets and monocytes in patients diagnosed with SARS-CoV-2 pneumonia: a mini review of the literature

.

Eur Rev Med Pharmacol Sci

.

2021 Aug

;

25

(

15

):

5057

–

62

.

131.

Kazancioglu

S

,

Yilmaz

FM

,

Bastug

A

,

Sakallı

A

,

Ozbay

BO

,

Buyuktarakci

C

,

Lymphocyte subset alteration and monocyte CD4 expression reduction in patients with severe COVID-19

.

Viral Immunol

.

2021 Jun

;

34

(

5

):

342

–

51

.

132.

Huang

CL

,

Fei

L

,

Li

W

,

Xu

W

,

Xie

XD

,

Li

Q

,

A novel prediction model for long-term SARS-CoV-2 RNA shedding in non-severe adult hospitalized patients with COVID-19: a retrospective cohort study

.

Infect Dis Ther

.

2021 Jun

;

10

(

2

):

897

–

909

.

133.

Sharma

A

,

Bhatt

NS

,

St Martin

A

,

Abid

MB

,

Bloomquist

J

,

Chemaly

RF

,

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

.

Lancet Haematol

.

2021 Mar

;

8

(

3

):

e185

–

93

.

134.

Zheng

M

,

Gao

Y

,

Wang

G

,

Song

G

,

Liu

S

,

Sun

D

,

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

.

Cell Mol Immunol

.

2020 May

;

17

(

5

):

533

–

5

.

135.

Huang

A

,

Bange

E

,

Han

N

,

Wileyto

EP

,

Kim

J

,

Gouma

S

,

CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer

.

Res Sq

.

2021 Feb 2

.

136.

Meir

J

,

Abid

MA

,

Abid

MB

.

State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses

.

Transplantation and Cellular Therapy

.

2021 Sep 27

.

137.

Buyuktas

D

,

Acar

K

,

Sucak

G

,

Toptas

T

,

Kapucu

I

,

Bekoz

H

,

COVID-19 infection in patients with acute leukemia; Istanbul experience

.

Am J Blood Res

.

2021 Aug 15

;

11

(

4

):

427

–

37

.

138.

Passamonti

F

,

Romano

A

,

Salvini

M

,

Merli

F

,

Porta

MGD

,

Bruna

R

,

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

.

Br J Haematol

.

2021 Nov

;

195

(

3

):

371

–

7

.

139.

Wang

B

,

Van Oekelen

O

,

Mouhieddine

TH

,

Del Valle

DM

,

Richter

J

,

Cho

HJ

,

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

.

J Hematol Oncol

.

2020 Jul 14

;

13

(

1

):

94

.

140.

Maurer

K

,

Saucier

A

,

Kim

HT

,

Acharya

U

,

Mo

CC

,

Porter

J

,

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience

.

Blood Adv

.

2021 Feb 9

;

5

(

3

):

861

–

71

.